“During recent months, we also started important clinical trials advancing later-stage development programs, setting us up to potentially ... Announced that Sanofi acquired from Corxel ...

Four years after Sanofi shelled out $125 million for global rights to Biond Biologic | The company is handing back the tumor ...

Novavax on Thursday posted a narrower fourth-quarter loss and said it expects its licensing deal with French drugmaker Sanofi ...

Just nine weeks after UnitedHealthcare CEO Brian Thompson was murdered on a weekday morning on a busy street, the luminaries ...

Immunology is a rapidly advancing field with significant potential for growth, especially in the realm of biotech and pharmaceutical companies.

Sanofi said the GEMINI 1 and 2 trials of tolebrutinib in relapsing forms of MS are fully enrolled and should read out in time to meet its plan of filing for regulatory approval in the US in 2024.

Sanofi has won FDA approval for its sutimlimab for cold agglutinin disease (CAD) at the second time of asking, becoming the first approved therapy for the rare blood disorder in the US.

Phase 1 healthy volunteer trial ongoing, complete SAD/MAD data expected in June 2025KT-621 Phase 1b trial in atopic dermatitis ...

Commercial Launch Preparations Advancing Prior to September 26 PDUFA Date; Regulatory Filings Under Review in U.S., Europe and ChinaTopline ...

Boulder-based Enveda Biosciences, which uses machine learning to discover naturally occurring drug compounds, recently added ...

DelveInsight's Advanced Therapy Medicinal Products Market Insights report provides the current and forecast market analysis, ...

DelveInsight's High Potency Active Pharmaceutical Ingredients Market Insights report provides the current and forecast market ...